Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 1;8(10):e2538277.
doi: 10.1001/jamanetworkopen.2025.38277.

Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies

Ka-Ho Wong  1   2 , Esther Zeng  3 , Tammy L Smith  1   4 , Jordan B King  2   5 , Erica Marini  6 , Abigail Sorenson  3 , Heewon Hwang  1 , Chloe Stein  1 , Trieste Francis  1 , John W Rose  1   4 , Vivek K Reddy  1 , Adam Helme de Havenon  7 , Stacey L Clardy  1   4
Affiliations

Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies

Ka-Ho Wong et al. JAMA Netw Open. .

Abstract

Importance: The expansion in the number of disease-modifying therapies (DMTs) for immune-mediated neurologic diseases raises critical questions about trends in their use and cost over time and whether this growth could be contributing to escalating financial burdens within the Medicare system.

Objective: To examine trends in claims and Medicare Part D payments for DMTs for immune-mediated neurologic diseases.

Design and setting: This retrospective economic evaluation analyzed Medicare Part D Prescriber Public Use Files from January 1, 2013, to December 31, 2022, restricting to prescription drug claims categorized under the clinician-defined neurology taxonomy. Only prescription drugs used as DMTs for multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated neurologic disorders were included. To ensure accuracy, these medications were validated by 2 pharmacists. The data were analyzed between October 1, 2023, and November 12, 2024.

Main outcomes and measures: Ten-year trends in total payments, number of claims, and payment per claim for DMTs were assessed for their contribution to overall cost increases. Inflation adjustments were applied using both medical care-specific and prescription drug-specific indices.

Results: Between 2013 and 2022, 63 unique drugs used as DMTs for multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated neurologic disorders (eg, autoimmune encephalitis, myasthenia gravis) accounted for 6 526 278 claims and contributed $35 billion in Medicare drug expenditures. Between 2013 and 2022, annual claims for DMTs increased by 3.8% (from 549 766 to 570 298 claims). However, total payments for DMTs saw a disproportionate increase of 70.3% (95% CI, 13.5%-130.3%) from 2013 to 2022. After adjusting for medical care or prescription drug inflation, 2022 payments per claim increased by 29.1% (95% CI, 15.6% to 51.6%) and 35.9% (95% CI, 29.5%-50.3%), respectively, indicating that the rise in drug costs exceeded adjustments for medical care or prescription drug inflation rates. For the 29 DMTs available over the entire 10-year period, total claims decreased by 14.8% (from 546 026 to 465 089). Despite this reduction in claims, total payments increased by 60.5% (95% CI, 50.9%-90.6%). After adjusting for medical care inflation, the total payment increased significantly by 26.2% (95% CI, 10.5%-49.4%).

Conclusions and relevance: Over the past decade, Medicare Part D expenditures for DMTs targeting immune-mediated neurologic diseases have increased substantially, despite relatively stable claim volumes. These findings show that increases have consistently outpaced inflation rates, adding substantial economic pressure to federally funded neurologic care.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Smith reported receiving advisory board fees from EMD Serono and grants from Alexion for research outside the submitted work. Dr de Havenon reported receiving personal fees from Novo Nordisk outside the submitted work, equity in TitinKM and Certus, and author fees from UpToDate. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Trends in Mean Payment Per Claim for Immune-Mediated Neurologic Disease-Modifying Therapies (63 Unique), 2013 to 2022
Shading indicates the 95% CI.
Figure 2.
Figure 2.. Trends in Mean Payment Per Claim for 29 Unique Immune-Mediated Neurologic Disease-Modifying Therapies That Were Available Consistently, 2013 to 2022
Shading indicates the 95% CI.
See this image and copyright information in PMC

References

    1. de Havenon A, Delic A, Dehoney S, et al. Five-Year trends in payments for neurologist-prescribed drugs in Medicare Part D. Neurology. 2021;96(16):e2132-e2137. doi: 10.1212/WNL.0000000000011712 - DOI - PMC - PubMed
    1. Hartung DM. Economics of multiple sclerosis disease-modifying therapies in the USA. Curr Neurol Neurosci Rep. 2021;21(7):28. doi: 10.1007/s11910-021-01118-x - DOI - PubMed
    1. Hartung DM. Health economics of disease-modifying therapy for multiple sclerosis in the United States. Ther Adv Neurol Disord. 2021;14:1756286420987031. doi: 10.1177/1756286420987031 - DOI - PMC - PubMed
    1. Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology. 2015;84(21):2185-2192. doi: 10.1212/WNL.0000000000001608 - DOI - PMC - PubMed
    1. Hartung DM, Johnston KA, Irwin A, Markwardt S, Bourdette DN. Trends in coverage for disease-modifying therapies for multiple sclerosis in Medicare Part D. Health Aff (Millwood). 2019;38(2):303-312. doi: 10.1377/hlthaff.2018.05357 - DOI - PubMed